Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16042213 | 0.83 | LPL (0.35) | LPLLIPGTSHR | |
| SCHEMBL16042255 | 0.81 | LPL (0.31) | LPLLIPG | |
| SCHEMBL16798702 | 0.81 | CYP1A2 (0.32) | LPLLIPG | |
| SCHEMBL29780026 | 0.81 | LPL (0.31) | LPLLIPG | |
| SCHEMBL12374406 | 0.79 | MAPK1 (0.39) | LPLLIPGMAPK1 | |
| SCHEMBL16042106 | 0.79 | EGFR (0.37) | — | |
| SCHEMBL12278668 | 0.79 | — | — | |
| SCHEMBL13730764 | 0.77 | MAPK1 (0.35) | LPLLIPGMAPK1 | |
| SCHEMBL26622502 | 0.77 | MAPK1 (0.38) | LPLLIPGMAPK1 | |
| SCHEMBL13785154 | 0.75 | MAPK1 (0.37) | LPLLIPGMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10106529-B2 | Compounds that modulate intracellular calcium | CALCIMEDIA, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106529-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | LPL 2534/4885LIPG 1985/4885MAPK1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.